

BVS Expand: First results of wide clinical applications of Bioresorbable Vascular Scaffold

Robert-jan van Geuns Thoraxcenter, ErasmusMC Rotterdam, The Netherlands On behalf of the Thoraxcenter Interventionalists and Yoshi Onuma, Roberto Diletti and Sjoerd Nauta

Thursday 23rd May, 2013 15:25-15:35





Potential conflicts of interest

Speaker's name: Robert-jan van Geuns


☑ I have the following potential conflicts of interest to report:

- Consultant: Stentys, Abbott Vascular
- Employment in industry: ...
- Honorarium: Speakersbureau, Stentys, Abbott Vascular
- Institutional grant/research support: Abbott Vascular
- Owner of a healthcare company: ...
- Stockholder of a healthcare company: ...



BVS Expand: Single Center Registry zafmas

- Larger diameter up to 4.0 mm
- Longer length: > 32 mm
- Bifurcations
- Calcified lesions
- ACS patients (non-STEMI)
- No previous CABG or metallic stent in target vessel




Disease Severity

Target: 300 patients Start Sept 1st 2013

BVS Expand: Single Center Registry 2 almost BVS-STEMI-First

- Single center registry BVS in STEMI
- OCT at baseline for apposition
- Dec 15th



Disease Severity

BVS Expand: Single Center Registry

<u>OBJECTIVE</u>

 This monocenter, prospective, observational post market registration will evaluate the long term safety and performance of the BVS coronary stent, in routine clinical practice. Its objective is to measure the incidence of Major Adverse Cardiac Events (MACE) patients with NSTEMI, stable or unstable angina, or silent ischemia

BVS Expand: Single Center Registry

<u>Primary Endpoint</u>

 Major Adverse Cardiac Events (MACE): defined as cardiac death, re-MI, emergent bypass surgery (CABG), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods at 12 months postprocedure



SECONDARY ENDPOINTS


- Success Rates:
 - <u>Device Success</u>: Attainment of <30% final residual stenosis of the segment of the culprit lesion covered by the BVS, by visual estimation
 - Procedure Success: Device success and no periprocedural complications
 - <u>Clinical success</u>: Procedural success and no inhospital MACE



SECONDARY ENDPOINTS

- Major Adverse Cardiac Events (MACE): defined as cardiac death, re-MI, emergent bypass surgery (CABG), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods **30 days**, 6, 12, 18 months, 2, 3, 4, and 5 years postprocedure
- Target vessel failure (TVF) defined as cardiac death, target vessel myocardial infarction (MI) [Q or Non Q-Wave], or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods at 30 days, 6, 12, 18 months, 2, 4 and 5 years.
- Health Related Quality-of-Life (HRQL) at 30 days, 6, 12 months, 3 and 5 years

BVS Expand + BVS-STEMI-First



Erasmus MC

zafing



Patient Inclusion

PCI Sep 1st 2013 – April 1st 2013

1018 procedures 958 patients

176 procedures with BVS 174 patients


Exclusion: Previous CABG: 2 patients

Exclusion:

STEMI requiring immediate stent implantation: 41 patients excluded, (42 procedures excluded)


BVS Expand 132 procedures 131 patients

Baseline characteristics



euro

PCR 2013



	BVS-Expand
Ν	131
Male	99 (75%)
Hypertension	68 (52%)
Hypercholestorolemia	61 (46%)
Diabetes	26 (20%)
Smoking	66 (50%)
Family	53 (40%)
Renal failure	9 (7%)
Prior MI	20 (15%)
Prior PCI	16 (12%)
Prior CABG	0 (0%)
Prior CVA	11 (8%)
PAD	15 (11%)
COPD	9 (7%)

Procedural characteristics

Implantation instruction

- Use online QCA
- Avoid under sizing, as postdilation is limited to 0.5 mm
- Proper lesion preparation = sufficient large balloon (min 2.5 mm)
- Use more supportive wires
- Direct stenting possible in ACS

Lesion Length: BVS EXPAND 20.3 mm (N=36)

	All (N=132)
MVD	39 (30%)
Bif	33 (25%)
СТО	11 (8%)
STEMI	0 (0%)
Overlap	46 (35%)
Total scaffolds	239
Scaffolds per procedure	1.8





SECONDARY ENDPOINTS

- Success Rates:
 - <u>Device Success</u>: Attainment of <30% final residual stenosis of the segment of the culprit lesion covered by the BVS, by visual estimation
 - Procedure Success: Device success and no periprocedural complications
 - <u>Clinical success</u>: Procedural success and no inhospital MACE



Procedural Outcome

	All (N=132)	
Device success	127 (96%)	Failure to Deliver
Procedural success	126 (95%)	One patient: DS>30%
Clinical success	126 (95%)	

Failure to deliver	All (N=5)
LCX	3
LAD	0
RCA	2

Procedural complications	All (N=1)
Side branch Occlusion	1 (1%)
MI	1 (1%)
Q-wave	0 (0
Non-Q-wave	1 (1%)

PCR 2013

30 Day outcome

Survival: 100%, FU completed for 80%

30 day outcome	BVS Expand (N=131)
MACE	1 (1%)
Target vessel failure	0 (%)
Cardiac death	0 (0%)
Any MI	1 (1%)
Emergent CABG	0 (0%)
iTLR	0 (0%)
Target vessel MI	0 (0%)
Non-TVR	1 (1%)

>30 days: 2 stent thromboses day 47 and day 120; 1 non-target vessel MI day 162; 1 death day 136. Survival status is available in 100% with a median follow-up of 137 days (IQR 96-195 days).

PCR 2013

Summary

- First real world experience in >130 complex procedures very positive following a strict implantation protocol
- At 30 days only one adverse event for these cases was reported
- Low MACE for current FU
- One death at 136 days, for median FU of 127 days
- Deliveribility:
 - Flexibilty
 - Crossing profile/Strut thickness
- Longer procedural time, more supportive wires, more predilatation.

PCR 2013

Bifurcations

	N = 132
Sidebranches >2 mm	33 (25%)
Sidebranches treated	19 (14.4%)
Balloon only	18 (13.6%)
2 scaffolds (Culotte)	1 (0.7%)



Failure to deliver

No of Patients

